Published in Br J Clin Pharmacol on February 01, 2001
Women encounter ADRs more often than do men. Eur J Clin Pharmacol (2008) 1.83
Pharmacokinetics and tolerability of voriconazole and a combination oral contraceptive co-administered in healthy female subjects. Br J Clin Pharmacol (2008) 1.16
Pregnancy and use of oral contraceptives reduces the biotransformation of proguanil to cycloguanil. Eur J Clin Pharmacol (2003) 1.15
Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping. Eur J Clin Pharmacol (2007) 1.14
The CYP2C19 genotype and the use of oral contraceptives influence the pharmacokinetics of carisoprodol in healthy human subjects. Eur J Clin Pharmacol (2005) 0.91
Measurement of CYP2D6 and CYP3A4 activity in vivo with dextromethorphan: sources of variability and predictors of adverse effects in 419 healthy subjects. Eur J Clin Pharmacol (2005) 0.88
CYP2C19 activity comparison between Swedes and Koreans: effect of genotype, sex, oral contraceptive use, and smoking. Eur J Clin Pharmacol (2010) 0.86
Effect of proton pump inhibitors on the serum concentrations of the selective serotonin reuptake inhibitors citalopram, escitalopram, and sertraline. Ther Drug Monit (2015) 0.83
Regulation of human CYP2C18 and CYP2C19 in transgenic mice: influence of castration, testosterone, and growth hormone. Drug Metab Dispos (2009) 0.83
Omeprazole limited sampling strategies to predict area under the concentration-time curve ratios: implications for cytochrome P450 2C19 and 3A phenotyping. Eur J Clin Pharmacol (2011) 0.80
Predictors of risperidone and 9-hydroxyrisperidone serum concentration in children and adolescents. J Child Adolesc Psychopharmacol (2011) 0.80
Effect of the novel anxiolytic drug deramciclane on cytochrome P(450) 2D6 activity as measured by desipramine pharmacokinetics. Eur J Clin Pharmacol (2004) 0.80
The effect of ethinyloestradiol and levonorgestrel on the CYP2C19-mediated metabolism of omeprazole in healthy female subjects. Br J Clin Pharmacol (2003) 0.79
Hydroxylation index of omeprazole in relation to CYP2C19 polymorphism and sex in a healthy Iranian population. Daru (2014) 0.79
Sex-dependent modulation of treatment response. Dialogues Clin Neurosci (2004) 0.77
Influence of carvedilol on serum digoxin levels in heart failure: is there any gender difference? Eur J Clin Pharmacol (2006) 0.76
Gender differences in pharmacokinetics and pharmacodynamics of methadone substitution therapy. Front Pharmacol (2015) 0.76
Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation. Clin Pharmacol Ther (1985) 2.50
Gender effects in pharmacokinetics and pharmacodynamics. Drugs (1995) 1.94
Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin Pharmacokinet (1995) 1.89
S-mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin. Clin Pharmacol Ther (1989) 1.41
CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences. Eur J Clin Pharmacol (1999) 1.06
Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities. Clin Pharmacol Ther (1989) 1.05
In-vivo indices of enzyme activity: the effect of renal impairment on the assessment of CYP2D6 activity. Pharmacogenetics (1999) 0.96
Evidence for the effect of gender on activity of (S)-mephenytoin 4'-hydroxylase (CYP2C19) in a Chinese population. Pharmacogenetics (1997) 0.95
Salivary analysis for determination of dextromethorphan metabolic phenotype. Clin Pharmacol Ther (1991) 0.92
A methodological investigation on the estimation of the S-mephenytoin hydroxylation phenotype using the urinary S/R ratio. Pharmacogenetics (1992) 0.91
Stimulatory as well as inhibitory effects of ethinyloestradiol on the metabolic clearances of propranolol in young women. Br J Clin Pharmacol (1996) 0.90
Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 phenotype polymorphisms. Eur J Clin Pharmacol (1997) 0.90
Genetic differences in drug disposition. J Clin Pharmacol (1994) 0.88
Interethnic differences in drug metabolism: influence of genetic and environmental factors on debrisoquine hydroxylation phenotype. Eur J Drug Metab Pharmacokinet (1996) 0.87
S-mephenytoin 4-hydroxylation in older Americans. Eur J Clin Pharmacol (1991) 0.84
Impairment of diazepam metabolism by low-dose estrogen-containing oral-contraceptive steroids. N Engl J Med (1982) 0.84
Assessment of individual CYP2D6 activity in extensive metabolizers with renal failure: comparison of sparteine and dextromethorphan. Clin Pharmacol Ther (1996) 0.84
Influence of oral contraceptives on drug therapy. Am J Obstet Gynecol (1990) 0.82
Fatal overdose with citalopram. Lancet (1996) 3.91
Association of venous thromboembolism and clozapine. Lancet (2000) 3.52
Attitudes to reporting adverse drug reactions in northern Sweden. Eur J Clin Pharmacol (2000) 1.72
Under-reporting of serious adverse drug reactions in Sweden. Pharmacoepidemiol Drug Saf (2004) 1.72
Effects of ibuprofen, diclofenac, naproxen, and piroxicam on the course of pregnancy and pregnancy outcome: a prospective cohort study. BJOG (2013) 1.58
HMG-CoA reductase inhibitors and myotoxicity. Drug Saf (2000) 1.51
Digitoxin medication and cancer; case control and internal dose-response studies. BMC Cancer (2001) 1.50
[The transfer of selective serotonin reuptake inhibitors to human milk]. Tidsskr Nor Laegeforen (2001) 1.44
Medication use in pregnancy: a cross-sectional, multinational web-based study. BMJ Open (2014) 1.41
Characterisation of zuclopenthixol metabolism by in vitro and therapeutic drug monitoring studies. Acta Psychiatr Scand (2010) 1.41
[Selective serotonin uptake inhibitors--are severe adverse effects a problem?]. Tidsskr Nor Laegeforen (2001) 1.39
[New intoxicants--new diagnostic challenges]. Tidsskr Nor Laegeforen (1998) 1.39
[Depression caused by beta blockaders. Unknown mechanisms behind well-known adverse effects]. Lakartidningen (1995) 1.38
Peripheral neurologic deficits in relation to subarachnoid or epidural administration of local anesthetics for surgery. A survey of 21 cases. Acta Anaesthesiol Scand (1997) 1.35
Comparison of theophylline and theobromine metabolism in man. Drug Metab Dispos (1986) 1.32
Decreased plasma protein binding of phenytoin in patients on valproic acid. Br J Clin Pharmacol (1979) 1.25
Nonlinear metabolic disposition of theophylline. Ther Drug Monit (1984) 1.16
Gender differences in drug effects: implications for anesthesiologists. Acta Anaesthesiol Scand (2003) 1.13
Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications. J Clin Psychiatry (1998) 1.10
Myocarditis related to clozapine treatment. J Clin Psychopharmacol (2001) 1.04
Intraindividual variability in the relative systemic availability of cyclosporin after oral dosing. Eur J Clin Pharmacol (1988) 1.03
Carbamazepine markedly reduces serum concentrations of simvastatin and simvastatin acid. Eur J Clin Pharmacol (2003) 0.98
Spontaneous reporting of adverse drug reactions by nurses. Pharmacoepidemiol Drug Saf (2002) 0.98
The effect of food and bile acid administration on the relative bioavailability of cyclosporin. Br J Clin Pharmacol (1990) 0.98
Pharmacokinetic properties of a new sustained-release theophylline preparation. Int J Clin Pharmacol Ther Toxicol (1983) 0.95
Inhibition of desipramine 2-hydroxylation by quinidine and quinine. Clin Pharmacol Ther (1988) 0.93
Effect of cigarette smoking on fluvoxamine pharmacokinetics in humans. Clin Pharmacol Ther (1995) 0.91
The paraxanthine:caffeine ratio in serum or in saliva as a measure of CYP1A2 activity: when should the sample be obtained? Pharmacogenetics (1999) 0.90
Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 phenotype polymorphisms. Eur J Clin Pharmacol (1997) 0.90
Separate and combined use of terbutaline and theophylline in asthmatics. Effects related to plasma levels. Eur J Respir Dis (1982) 0.87
Effect of quinidine on plasma concentration and renal clearance of digoxin. A clinically important drug interaction. Br J Clin Pharmacol (1980) 0.86
Oral symptoms in bulimia nervosa. A survey of 34 cases. Acta Odontol Scand (1991) 0.86
DMSA administration to patients with alleged mercury poisoning from dental amalgams: a placebo-controlled study. J Dent Res (1994) 0.86
Effects of comedication on the serum levels of aripiprazole: evidence from a routine therapeutic drug monitoring service. Pharmacopsychiatry (2007) 0.86
Pharmacokinetics of digoxin in patients subjected to the quinidine-digoxin interaction. Br J Clin Pharmacol (1981) 0.85
Maternal characteristics and migraine pharmacotherapy during pregnancy: cross-sectional analysis of data from a large cohort study. Cephalalgia (2009) 0.85
Paroxetine level in breast milk. J Clin Psychiatry (1996) 0.85
Lack of correlation between fluvoxamine clearance and CYP1A2 activity as measured by systemic caffeine clearance. Eur J Clin Pharmacol (1999) 0.85
Theophylline in maintenance treatment of chronic asthma: concentration-dependent additional effect to beta 2-agonist therapy. Eur J Respir Dis (1987) 0.85
Peripheral sensory disturbances related to treatment with fluoroquinolones. J Antimicrob Chemother (1996) 0.84
Theophylline metabolism in relation to antipyrine, debrisoquine, and sparteine metabolism. Clin Pharmacol Ther (1984) 0.84
Excretion of paroxetine into breast milk. J Clin Psychiatry (1999) 0.83
Reduced effect of warfarin caused by ubidecarenone. Lancet (1994) 0.82
Interactions in the renal and biliary elimination of digoxin: stereoselective difference between quinine and quinidine. Clin Pharmacol Ther (1990) 0.82
Quinidine reduces biliary clearance of digoxin in man. Eur J Clin Invest (1987) 0.81
Pharmacokinetics of intraperitoneally instilled aminophylline, terbutaline and tobramycin in pigs. Acta Anaesthesiol Scand (2007) 0.80
Pharmacokinetics of progesterone and its metabolites allopregnanolone and pregnanolone after oral administration of low-dose progesterone. Maturitas (2006) 0.80
Ventricular fibrillation related to reversal of the neuromuscular blockade in a patient with long QT syndrome. Acta Anaesthesiol Scand (1999) 0.80
Absence of interaction between erythromycin and a single dose of clozapine. Eur J Clin Pharmacol (1999) 0.80
Digoxin-verapamil interaction: reduction of biliary but not renal digoxin clearance in humans. Clin Pharmacol Ther (1991) 0.80
Serotonin syndrome induced by fluvoxamine-lithium interaction. Pharmacopsychiatry (1993) 0.79
Citalopram pharmacokinetics in patients with chronic renal failure and the effect of haemodialysis. Eur J Clin Pharmacol (2000) 0.79
Non-linear fluvoxamine disposition. Br J Clin Pharmacol (1998) 0.78
A prospective study of cyclosporine concentration in relation to its therapeutic effect and toxicity after renal transplantation. Br J Clin Pharmacol (1990) 0.78
[The role of serotonin in normal appetite regulation and in the pathogenesis of anorexia/bulimia]. Nord Med (1990) 0.78
Incorrect use and limited weight reduction of orlistat (Xenical) in clinical practice. A cohort study. Eur J Clin Pharmacol (2001) 0.78
Seizures and myoclonus associated with antidepressant treatment: assessment of potential risk factors, including CYP2D6 and CYP2C19 polymorphisms, and treatment with CYP2D6 inhibitors. Acta Psychiatr Scand (1997) 0.77
A case of fluvoxamine intoxication demonstrating nonlinear elimination pharmacokinetics. J Clin Psychopharmacol (1996) 0.77
Digoxin-interactions in man: spironolactone reduces renal but not biliary digoxin clearance. Eur J Clin Pharmacol (1992) 0.77
Olanzapine disposition in humans is unrelated to CYP1A2 and CYP2D6 phenotypes. Eur J Clin Pharmacol (2001) 0.77
Fluvoxamine is a potent inhibitor of tacrine metabolism in vivo. Eur J Clin Pharmacol (1999) 0.77
Lack of influence of menstrual cycle and premenstrual syndrome diagnosis on pregnanolone pharmacokinetics. Eur J Clin Pharmacol (1999) 0.76
Influence of postmenopausal hormone replacement therapy on platelet serotonin uptake site and serotonin 2A receptor binding. Obstet Gynecol (2001) 0.76
Anticonvulsant use during lactation. Drug Saf (2000) 0.76
Binding of [3H]paroxetine to serotonin uptake sites and of [3H]lysergic acid diethylamide to 5-HT2A receptors in platelets from women with premenstrual dysphoric disorder during gonadotropin releasing hormone treatment. Psychoneuroendocrinology (2001) 0.76
The major fluvoxamine metabolite in urine is formed by CYP2D6. Eur J Clin Pharmacol (2001) 0.76
Hyponatremia during treatment with clomipramine, perphenazine, or clozapine: study of therapeutic drug monitoring samples. J Clin Psychopharmacol (1996) 0.76
Utilization pattern of metamizole in northern Sweden and risk estimates of agranulocytosis. Pharmacoepidemiol Drug Saf (2002) 0.76
No effect of probenecid on the renal and biliary clearances of digoxin in man. Br J Clin Pharmacol (1991) 0.75
[Antidepressive agents and breast feeding]. Tidsskr Nor Laegeforen (1998) 0.75
[Folic acid deficiency, cancer and congenital abnormalities]. Tidsskr Nor Laegeforen (1996) 0.75
Platelet [3H]paroxetine and [3H]lysergic acid diethylamide binding in seasonal affective disorder and the effect of bright light therapy. Biol Psychiatry (1999) 0.75
Death resulting from asthma associated with sertraline "overdose". Am J Forensic Med Pathol (2001) 0.75
Co-ordinating editor's comments on the letter to the editors by A. Herxheimer. Eur J Clin Pharmacol (2000) 0.75
Medicine Cabinet: Drug treatment of depression. West J Med (1999) 0.75
Risperidone metabolism and the impact of being a cytochrome P450 2D6 ultrarapid metabolizer. J Clin Psychiatry (2000) 0.75
Effect of caffeine on clozapine pharmacokinetics in healthy volunteers. Br J Clin Pharmacol (2000) 0.75
[Bulimia. A review of the literature]. Tidsskr Nor Laegeforen (1986) 0.75
[How important is following the physician's instructions? Demands on patients vary among different individual groups]. Lakartidningen (1993) 0.75
Urinary excretion of codeine, ethylmorphine, and their metabolites: relation to the CYP2D6 activity. Ther Drug Monit (1997) 0.75
Increased glucose intolerance related to digoxin treatment in patients with type 2 diabetes mellitus. J Intern Med (1999) 0.75
[A regional center for reporting adverse drug reactions in Umeå. Prompt handling results in quick feedback]. Lakartidningen (1995) 0.75
[Bulimia and destruction of dental hard tissues]. Nor Tannlaegeforen Tid (1987) 0.75
[3H]GBR 12935 binding in platelets from poor and extensive cytochrome P-4502D6 metabolizers. Eur J Pharmacol (1999) 0.75
Binding of [(3)H]lysergic acid diethylamide to serotonin 5-HT(2A) receptors and of [(3)H]paroxetine to serotonin uptake sites in platelets from healthy children, adolescents and adults. Neuropsychobiology (1999) 0.75
Indomethacin but not metoprolol reduces exercise-induced albumin excretion rate in type 1 diabetic patients with microalbuminuria. Diabet Med (1993) 0.75
Theophylline--plasma concentration related to bronchodilatation and side effects. Prax Klin Pneumol (1983) 0.75
Prolonged sedation and slowly decreasing clozapine serum concentrations after an overdose. J Clin Psychopharmacol (1999) 0.75
Are adverse drug reactions attributed to fluvoxamine caused by concomitant intake of caffeine? Eur J Clin Pharmacol (1998) 0.75
[Parallel import of drugs]. Tidsskr Nor Laegeforen (1999) 0.75
Cardiac effects of treatment with quinidine and digoxin, alone and in combination. Am J Cardiol (1983) 0.75
Neurologic oral manifestations caused by a new formulation of mirtazapine. Neurology (2005) 0.75
[Urinary incontinence. A study of occurrence in the municipality of Sund]. Tidsskr Nor Laegeforen (1989) 0.75